XENE

37.0401.38%
DA

Dawn A. Svoronos

Non-Executive Independent Director

Ms. Dawn A. Svoronos, also known as Graham, is Director of AgNovos Healthcare, LLC. She serves as Non-Executive Independent Director of Lakefront Biotherapeutics NV (formerly known as Galapagos NV) since July 28, 2025. She has been an Independent Director of ACELYRIN, INC. since December 01, 2022. Ms. Svoronos served as an Independent Director at Adverum Biotechnologies, Inc. since December 2020 until December 9, 2025. She served as Independent Director of Global Blood Therapeutics, Inc. since December 21, 2018 until October 05, 2022. Ms. Svoronos served as Director of Endocyte, Inc. since May 3, 2018 until December 21, 2018. She served as an Interim Chief Commercial Officer of Medivation, Inc. from July 10, 2014 to December 8, 2014. Ms. Svoronos has experience in the pharmaceutical industry, including extensive commercial work with the multinational pharmaceutical company Merck & Co. Inc., where she held roles of increasing seniority of service. Prior to her retirement from Merck in March 2011, she served as President of Merck in Europe/Canada from 2009 to 2011, President of Merck Canada Inc. from September 2006 to 2009 and Vice-President of Merck for Asia Pacific from 2005 to 2006. She served as President of the Europe/Canada region for Merck & Co. Ms. Svoronos was President of Merck in Canada. Prior to joining Merck Frosst in 1988, she worked as a sales Representative, has held a number of positions of increasing responsibility at Merck Frosst Canada Ltd. in the area of sales, marketing, government relations and public affairs. From 2004 to 2006, she worked for the Global Headquarters of Merck & Co. Inc. in Whitehouse Station, NJ., as Vice President of Global Marketing for the Arthritis & Analgesia and Osteoporosis franchises. Since 2005, she served as a Vice President of Asia Pacific for Merck & Co. Inc. She had been Independent Chair of the Board of Theratechnologies Inc. since May 24, 2013 until May 9, 2024. She served as the Chair of Centre for Drug Research and Development. She serves as the Chairman of Canada’s Research-Based Pharmaceutical Companies (Rx&D). She had been an Independent Director of PTC Therapeutics, Inc. since June 13, 2016 until December 6, 2022. She serves as Independent Director of Xenon Pharmaceuticals Inc. since September 27, 2016 and serves as its Chairman since June 2024. She served as Lead Independent Director at Xenon Pharmaceuticals Inc. since June 2021 until June 2024. She serves as a Director of Rx&D. She has been an Independent Director at Theratechnologies Inc. since April 8, 2013. She serves as a Member of the Board of Directors of AgNovos Healthcare Company. She served as a Director of Medivation, Inc. since April 23, 2013 until September 28, 2016. In 2009, she was elected “one of the most powerful women in Canada” by the Canadian Women’s Executive Network. Ms. Svoronos received a B.A. in English and French Literature from Carleton University.

Positions